Thrombospondin-1 and transforming growth factor-β levels in prolactinoma and their clinical significance

Journal of International Medical Research

Volumn 40, Issue 4, 2012, Pages 1284-1294

  Jiang, M ^a   Mou, C Z ^a   Han, T ^a   Wang, M ^a   Yang, W ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Invasiveness; Microvessel density; Prolactinoma; Thrombospondin 1

Indexed keywords

THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA1;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER INVASION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; PROLACTINOMA; PROTEIN ANALYSIS; WESTERN BLOTTING;

EID: 84867513406     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/147323001204000407     Document Type: Article

References (45)

1. Schlechte JA: Clinical practice. Prolactinoma. N Engl J Med 2003; 349: 2035 - 2041.
2. Barker FG 2nd, Klibanski A, Swearingen B: Trans-sphenoidal surgery for pituitary tumors in the United States, 1996 - 2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab 2003; 88:4709-4719. (Pubitemid 37357516)
3. Ahmadi J, North CM, Segall HD, et al: Cavernous sinus invasion by pituitary adenomas. AJR Am J Roentgenol 1986; 146: 257 -262.
4. Gürlek A, Karavitaki N, Ansorge O, et al: What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. Eur J Endocrinol 2007; 156: 143 153.
5. Offersen BV, Borre M, Overgaard J: Quantification of angiogenesis as a prognostic marker in human carcinomas: A critical evaluation of histopathological methods for estimation of vascular density. Eur J Cancer 2003; 39: 881 - 890.
6. Weis SM, Cheresh DA: Tumor angiogenesis: Molecular pathways and therapeutic targets. Nat Med 2011; 17: 1359 - 1370.
7. Svagzdys S, Lesauskaite V, Pavalkis D, et al: Microvessel density as new prognostic marker after radiotherapy in rectal cancer. BMC Cancer 2009; 9: 95.
8. Pakalniskis MG, Wells WA, Schwab MC, et al: Tumor angiogenesis change estimated by using diffuse optical spectroscopic tomography: Demonstrated correlation in women undergoing neoadjuvant chemotherapy for invasive breast cancer? Radiology 2011; 259: 365 - 374.
9. Turner HE, Nagy Z, Gatter KC, et al Angiogenesis in pituitary adenomas and the normal pituitary gland. J Clin Endocrinol Metab 2000; 85: 1159-1162.
10. Turner HE, Nagy Z, Gatter KC, et al: Angiogenesis in pituitary adenomas relationship to endocrine function, treatment and outcome. J Endocrinol 2000; 165: 475 - 481.
11. Takada K, Yamada S, Teramoto A: Correlation between tumor vascularity and clinical findings in patients with pituitary adenomas. Endocr Pathol 2004; 15: 131 - 139.
12. Mosher DF, Doyle MJ, Jaffe EA: Synthesis and secretion of thrombospondin by cultured human endothelial cells. J Cells Biol 1982; 93: 343 - 348.
13. Jaffe EA, Ruggiero JT, Leung LK, et al: Cultured human fibroblasts synthesize and secrete thrombospondin and incorporate it into extracellular matrix. Proc Natl Acad Sci USA 1983; 80: 998 - 1002.
14. Jaffe EA, Ruggiero JT, Falcone DJ: Monocytes and macrophages synthesize and secrete thrombospondin. Blood 1985; 65: 79 - 84.
15. Silverstein RL, Nachman RL: Thrombospondin binds to monocytes-macrophages and mediates platelet-monocyte adhesion. J Clin Invest 1987; 79: 867 - 874.
16. Taraboletti G, Roberts D, Liotta LA, et al: Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: A potential angiogenesis regulatory factor. J Cell Biol 1990; 111: 765 - 772.
17. Guo N, Krutzsch HC, Inman JK, et al: Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res 1997; 57: 1735-1742. (Pubitemid 27199668)
18. Lawler J: Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell MoI Med 2002; 6: 1 - 12.
19. Verrecchia F, Mauviel A: Transforming growth factor-β signaling through the Smad pathway: Role in extracellular matrix gene expression and regulation. J Invest Dermatol 2002; 118: 211 -215.
20. Derynck R, Akhurst RJ, Balmain A: TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001; 29: 117 - 129.
21. Adams JC, Tucker RP: The thrombospondin type 1 repeat (TSR) superfamily: Diverse proteins with related roles in neuronal development. Dev Dyn 2000; 218: 280 - 299.
22. Kawataki T, Naganuma H, Sasaki A, et al: Correlation of thrombospondin-1 and transforming growth factor-β expression with malignancy of glioma. Neuropathology 2000; 20: 161 - 169.
23. Miyanaga K, Kato Y, Nakamura T, et al: Expression and role of thrombospondin-1 in colorectal cancer. Anticancer Res 2002; 22: 3941 - 3948.
24. Hardy J: Transphenoidal microsurgical treatment of pituitary tumours. In: Recent Advances in the Diagnosis and Treatment of Pituitary Tumours ( Linfoot J, ed). New York: Raven Press, 1979; pp 375 - 388.
25. Nakao T, Kurita N, Komatsu M, et al: Expression of thrombospondin-1 and Ski are prognostic factors in advanced gastric cancer. Int J Clin Oncol 2011; 16: 145-152.
26. Weidner N: Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995; 147: 9 - 19.
27. Cavallaro U, Christofori G: Molecular mechanisms of tumor angiogenesis and tumor progression. J Neurooncol 2000; 50: 63 - 70.
28. Chen ZJ, Le HB, Zhang YK, et al: Microvessel density and expression of thrombospondin-1 in non-small cell lung cancer and their correlation with clinicopathological features. J int Med Res 2009; 37: 551 - 556.
29. White JD, Hewett PW, Kosuge D, et al: Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. Cancer Res 2002; 62: 1669 - 1675.
30. Kim JH, Seo JS, Lee BW, et al: The characteristics of incidental pituitary microadenomas in 120 Korean forensic autopsy cases. J Korean Med Sci 2007; 22( suppl): S61 - S65.
31. Jugenburg M, Kovacs K, Stefaneanu L, et al: Vasculature in nontumorous hypophyses, pituitary adenomas, and carcinomas: A quantitative morphologic study. Endocr Pathol 1995; 6: 115-124.
32. Vidal S, Kovacs K, Horvath E, et al: Microvessel density in pituitary adenomas and carcinomas. Virchows Arch 2001; 438: 595 - 602.
33. Viacava P, Gasperi M, Acerbi G, et al: Microvascular density and vascular endothelial growth factor expression in normal pituitary tissue and pituitary adenomas. J Endocrinol Invest 2003; 26: 23 - 28.
34. Good DJ, Polverini PJ, Rastinejad F, et al: A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990; 87: 6624 - 6628.
35. Fontana A, Filleur S, Guglielmi J, et al: Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo. Int J Cancer 2005; 116: 686 - 691.
36. Febbraio M, Hajjar DP, Silverstein RL: CD36: A class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest 2001; 108: 785 - 792.
37. Reed MJ, Iruela-Arispe L, O'Brien ER, et al: Expression of thrombospondins by endothelial cells. Injury is correlated with TSP-I. Am J Pathol 1995; 147: 1068 - 1080.
38. Miao WM, Seng WL, Duquette M, et al: Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-β-dependent and -independent mechanisms. Cancer Res 2001; 61: 7830 - 7839.
39. Nicosia RF, Tuszynski GP: Matrix-bound thrombospondin promotes angiogenesis in vitro. J Cell Biol 1994; 124: 183 - 193.
40. Streit M, Velasco P, Brown LF, et al: Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am J Pathol 1999; 155:441-452. (Pubitemid 29370394)
41. Wang XQ, Lindberg FP, Frazier WA: Integrinassociated protein stimulates α2βl-dependent Chemotaxis via Gi-mediated inhibition of adenylate cyclase and extracellular-regulated kinases. J Cell Biol 1999; 147: 389 - 400.
42. Akhurst RJ, Derynck R: TGF-β signaling in cancer - A double-edged sword. Trends Cell Biol 2001; 11: S44-S51.
43. Breier G, Blum S, Peli J, et al: Transforming growth factor-β and Ras regulate the VEGF/VEGF-receptor system during tumor angiogenesis. Int J Cancer 2002; 97: 142 - 148.
44. Hasegawa Y, Takanashi S, Kanehira Y, et al: Transforming growth factor-β level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer 2001; 91: 964 - 971.
45. Xiong B, Gong LL, Znang F, et al: TGF β expression and angiogenesis in colorectal cancer tissue. World J Gastroenterol 2002; 8: 496 -498.